Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftobiprole versus cefepime with or without vancomycin for fever and neutropenia
2007-003464-22Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2007
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in febrile neutropenia (FN) comparing Ceftobiprole medocaril with Cefepime with or without vancomycin (2 arms). Primary endpoints: Clinical cure rate without modification of initial therapy and Clinical cure rate at the primary efficacy visit regardless of modification of therapy. Started Aug 2007; status: completed.
02
Drugs
ceftobiprole medocarilcefepimevancomycin
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on 2007-003464-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003464-22.